Related references
Note: Only part of the references are listed.Imeglimin increases glucose-dependent insulin secretion and improves β-cell function in patients with type 2 diabetes
G. Pacini et al.
DIABETES OBESITY & METABOLISM (2015)
Imeglimin Normalizes Glucose Tolerance and Insulin Sensitivity and Improves Mitochondrial Function in Liver of a High-Fat, High-Sucrose Diet Mice Model
Guillaume Vial et al.
DIABETES (2015)
The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Sitagliptin Monotherapy
Pascale Fouqueray et al.
DIABETES CARE (2014)
The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
Pascale Fouqueray et al.
DIABETES CARE (2013)
Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients
V. Pirags et al.
DIABETES OBESITY & METABOLISM (2012)
The dual control of insulin secretion by glucose involves triggering and amplifying pathways in β-cells
Jean-Claude Henquin
DIABETES RESEARCH AND CLINICAL PRACTICE (2011)
Imeglimin - A New Oral Anti-Diabetic that Targets the Three Key Defects of Type 2 Diabetes
Pascale Fouqueray et al.
JOURNAL OF DIABETES & METABOLISM (2011)
Resistance to High-Fat Diet-Induced Obesity and Insulin Resistance in Mice with Very Long-Chain Acyl-CoA Dehydrogenase Deficiency
Dongyan Zhang et al.
CELL METABOLISM (2010)
Regulation of insulin secretion: role of mitochondrial signalling
S. Jitrapakdee et al.
DIABETOLOGIA (2010)
Phosphoenolpyruvate Cycling via Mitochondrial Phosphoenolpyruvate Carboxykinase Links Anaplerosis and Mitochondrial GTP with Insulin Secretion
Romana Stark et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Triggering and amplifying pathways of regulation of insulin secretion by glucose
JC Henquin
DIABETES (2000)
Share Paper
